Owens & Minor shareholders approve board appointments

Owens & Minor Inc. (NYSE:OMI), a healthcare logistics company, held its 2025 Annual Meeting of Shareholders on May 15, where several key proposals were approved. The meeting saw a high turnout with approximately 92.66% of shares entitled to vote being represented.

The election of nine directors for a one-year term was one of the primary items on the agenda. Each director received a substantial majority of votes in favor, with Mark A. Beck receiving 65,156,358 votes for and 1,190,566 against, exemplifying the trend among all nominees. Broker non-votes were reported at 5,204,737 for each director, indicating that brokers did not exercise discretionary voting on these matters.

Additionally, the shareholders ratified the appointment of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal received an overwhelming number of affirmative votes, with 69,530,274 votes for, 1,961,932 against, and 90,742 abstentions.

An advisory vote to approve the compensation of Owens & Minor’s named executive officers also passed, with 63,157,616 votes for, 3,148,361 against, and 72,234 abstentions. There were 5,204,737 broker non-votes on this proposal.

The results demonstrate shareholder confidence in the company’s leadership and financial oversight practices. The approval of executive compensation also suggests shareholder agreement with the company’s pay structure for its executives. According to InvestingPro data, while the company carries a significant debt burden of $2.27 billion, analysts expect a return to profitability this year despite challenging market conditions that have led to a -45.75% year-to-date return.

This news is based on a press release statement and the information has been summarized for clarity. For deeper insights into Owens & Minor’s financial health and future prospects, including 7 additional exclusive ProTips and comprehensive valuation metrics, explore the full analysis available on InvestingPro.

In other recent news, Owens & Minor Inc. reported its first-quarter 2025 financial results, surpassing earnings expectations. The company posted an earnings per share (EPS) of $0.23, exceeding the forecast of $0.20, although revenues of $2.63 billion fell slightly short of the anticipated $2.66 billion. The company experienced a 1% year-over-year revenue increase, attributed to strong performance in its Patient Direct segment. Owens & Minor is also set to acquire RoTEK, with the deal expected to close in the first half of 2025, as the company continues to expand its product offerings into new therapy areas.

Additionally, Owens & Minor reaffirmed its full-year guidance, anticipating that 70% of its earnings and cash flow will be generated in the latter half of the year. The company remains engaged in discussions regarding the potential sale of its Products and Healthcare Services (NASDAQ:HCSG) segment. Analyst feedback from firms such as JPMorgan and Citi has focused on the company’s tariff exposure, estimated to be between $100 million and $150 million, with plans to implement price increases to offset these costs. Owens & Minor’s strategic initiatives include leveraging its U.S. manufacturing footprint and exploring alternative sourcing options to mitigate tariff impacts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.